Table 5.

Adjusted change in mineral metabolism measurements for black and nonblack patients across two time periods

OutcomePre-PPS: Monthly Δ (95% CI), August 2010–December 2010Post-PPS: Monthly Δ (95% CI), January 2011–December 2011 Post-PPSP Value Difference in Trends by Race
NonblackBlackNonblackBlack
PTH (pg/ml)13.15 (8.99 to 17.31)18.31 (8.01 to 28.60)1.14 (−1.27 to 3.56)1.11 (−2.53 to 4.76)0.59
Patients with PTH>600 pg/ml (%)0.93 (0.35 to 1.50)1.61 (0.63 to 2.58)0.17 (−0.04 to 0.39)−0.00 (−0.33 to 0.33)0.39
Patients with IV vitamin D use (%)−0.70 (−1.47 to 0.06)0.26 (−0.59 to 1.11)0.38 (0.10 to 0.66)0.23 (−0.07 to 0.53)0.22
Prescribed vitamin D dose (μg/wk)0.46 (0.12 to 0.81)0.74 (−0.01 to 1.49)0.21 (0.06 to 0.36)0.13 (−0.10 to 0.36)0.53
Delivered vitamin D dose (μg/wk)a0.48 (0.06 to 0.90)1.17 (0.16 to 2.17)0.26 (0.08 to 0.44)0.18 (−0.02 to 0.38)0.28
Patients with cinacalcet use (%)−0.18 (−0.74 to 0.38)−0.21 (−0.95 to 0.54)0.04 (−0.20 to 0.29)0.08 (−0.34 to 0.50)0.99
Patients with phosphate binder use (%)−0.94 (−1.62 to −0.25)−0.66 (−1.78 to 0.45)0.26 (−0.11 to 0.63)0.36 (−0.09 to 0.80)0.83
  • Models adjusted for age, sex, predialysis weight, years since dialysis initiation, geographic region, and ESRD cause. 95% CI, 95% confidence interval.

  • a Based on a subset of facilities for which data were available.